BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy
BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outsideCellink AB. Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company operates as a provider of advanced bioprinting solutions for healthcare sector. The Company offers 3D bioprinting of human tissues and organs. The Company's technology facilitates the biofabrication of cell-laden anatomical structures with controlled cell density and homogenous distribution of viable cells. The cell-laden bioink structures are then cultured in vitro, under controlled conditions for a wide range of experiments. In addition, bioprinting with human cells can be combined with computer-aided design (CAD) and computer-aided manufacturing (CAM) using medical images from CT or MRI scans to create a blueprint (3D model) for bioprinting of patient-specific tissues and organs.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.